Author Information
Mark John Smyth is a distinguished researcher affiliated with the Immunology in Cancer and Infection Laboratory at the QIMR Berghofer Medical Research Institute in Queensland, Australia. His research primarily focuses on the intersection of immunology and cancer, exploring mechanisms of tumor immunosuppression, antitumor immunity, and the role of immune cells in the tumor microenvironment.Research Contributions
Mark John Smyth has made significant contributions to the field of cancer immunotherapy and tumor immunology. His recent publications in 2021 and 2022 include groundbreaking work on the role of CD155 in tumor suppression, the importance of NKG7 for optimal antitumor T-cell immunity, and the enhancement of immune checkpoint blockade therapy through dietary Lactobacillus-derived exopolysaccharides. Smyth's research also delves into the characterization of CD8 T cell-mediated mutations, the impact of ATP on cancer immunosurveillance, and the implications of SARS-CoV-2 mutations on immune responses. His work is highly regarded and frequently cited, demonstrating a profound impact on cancer and infection immunology.Aliases
Mark John Smyth is known by several aliases in academic publications, including M Smyth, Markj. Smyth, Mark J. Smyth, M. J. Smyth, M J Smyth, Mark\u2004j. Smyth, Mark J Smyth, and Mark Smyth.Publication and Citation Metrics
| Metric |
Value |
| Total Citations |
100,299 |
| h-index |
162 |
| Total Papers |
864 |
